Asymchem(SZ:002821)2023-05-05 10:26Group 1: Financial Performance - In Q1 2023, the company achieved total revenue of CNY 2.249 billion, representing a year-on-year growth of 9.09% [3] - The net profit attributable to shareholders reached CNY 630 million, with a year-on-year increase of 26.2% [3] - Adjusted net profit was CNY 701 million, reflecting a year-on-year growth of 26.7% [3] - The gross margin improved to 48.4%, an increase of 3.16% compared to the previous year [3] Group 2: Business Segments - The small molecule CDMO business generated revenue of CNY 2.000 billion, showing slight growth; excluding large orders, revenue increased by 45.37% [3] - Revenue from large pharmaceutical companies grew by over 60% year-on-year [3] - Emerging business segments saw an overall revenue increase of 72.54% [3] Group 3: Future Outlook - The company anticipates challenges in maintaining performance due to a high base from the previous year and the delivery of large orders [3] - Confidence remains in the growth of the small molecule CDMO business and the emerging business segments [3] - The company plans to focus on deepening relationships with major clients, particularly large pharmaceutical companies, as a key growth driver [3] Group 4: Investor Engagement - The investor relations activity included participation from over 100 institutions, including major securities firms and funds [1] - The meeting was held on May 4, 2023, with key executives present to address investor inquiries [2] Group 5: Capital Expenditure - The expected capital expenditure for 2023 is projected to be 15-20% of revenue, with over half allocated to emerging business segments [4] - Capital expenditure for 2024 is anticipated to be controlled within 20% of that year's revenue [4]